Press Releases
Keyword Search
 
2016 | 2015 | 2014
DateTitle 
02/11/16Collegium Announces Favorable Judgment by the District Court of Massachusetts
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application ... 
Printer Friendly Version
02/04/16Collegium Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza™ ER CANTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the U.S. Patent and Trademark Office (USPTO). The issued patent covers the DETERx technology platform and Collegium's lead product candidate, Xtampza ER (oxycodone) extended-release capsules. The claims... 
Printer Friendly Version
02/02/16Collegium Provides Litigation Update
CANTON, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On February 1, 2016, the U.S. Court of Appeals for the Federal Circuit rendered its decision to uphold a prior ruling from the U.S. District Court of the Southern District of New York that invalidated four patents associated with OxyContin OP, including Purdue’s three Orange Book-listed patents asserted again... 
Printer Friendly Version
01/25/16Collegium Appoints Ted Schroeder to Board of Directors
CANTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led specialty pharmaceutical company Cadence Pharmaceuticals from its founding until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. Most recently, Mr. Schroeder co-founded Zavante Therapeutics, which is developing its antibiotic candidate ZTI-01. "Ted has significant experience in th... 
Printer Friendly Version
01/21/16Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx®
Second Clinical Candidate to Leverage DETERx Technology Platform CANTON, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin a clinical trial of Hydrocodone DETERx®, an abuse-deterrent, extended-release analgesic for the treatment of chronic pain. This proof of concept clinical trial is intended to evaluate the safety... 
Printer Friendly Version
01/08/16Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock
CANTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price to the public of $20.00 per share, before underwriting discounts and commissions. The gross proceeds of this offering are expected to be $55.0 million. All of the shares in this offering are being sold by Collegium.  In addition, Collegium has granted the underwriters a 30-day option to purchase from ... 
Printer Friendly Version